专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07270966B2 Human pyrimidine receptor 有权
标题翻译：人嘧啶受体
公开(公告)号：US07270966B2
公开(公告)日：2007-09-18
申请号：US10753695
申请日：2004-01-08
申请人： Didier Communi , Marc Parmentier , Jean-Marie Boeynaems , Sabine Pirotton
发明人： Didier Communi , Marc Parmentier , Jean-Marie Boeynaems , Sabine Pirotton
IPC分类号： G01N33/53 , C12Q1/68
CPC分类号： C07K14/705 , A01K2217/05 , A01K2217/075 , C12N2310/14
摘要： This invention provides a receptor having a preference for pyrimidine nucleotides preferably uridine triphosphate over purine nucleotides. A receptor having a preference for pyrimidine nucleotides over purine nucleotides means a receptor for which pyrimidine nucleotides and purine nucleotides are not equally active and equipotent. This means that the receptor according to the invention in presence of these agonists presents a functional response (preferably the accumulation of Inositol triphosphate (IP3), diacylglycerol (DAG), or calcium ions) to lower concentration of pyrimidine nucleotides, preferably uridine triphosphate, than to purine nucleotides or a more important functional response to similar concentration of pyrimidine nucleotide than to purine nucleotide
摘要翻译：本发明提供了对嘌呤核苷酸优先选择嘧啶核苷酸优选尿苷三磷酸的受体。对嘌呤核苷酸优先选择嘧啶核苷酸的受体是指嘧啶核苷酸和嘌呤核苷酸不具有同等活性和等同性的受体。这意味着在这些激动剂存在下，根据本发明的受体具有功能性反应（优选三聚磷酸肌醇（IP3），二酰基甘油（DAG）或钙离子）的积累）以降低嘧啶核苷酸浓度，优选尿苷三磷酸嘌呤核苷酸或与嘌呤核苷酸相似浓度的嘧啶核苷酸的更重要的功能反应

2. 发明申请

US20070044166A1 P2Y4 Receptor transgenic and knockout non-human mammals 审中-公开
标题翻译： P2Y4受体转基因和敲除非人哺乳动物
公开(公告)号：US20070044166A1
公开(公告)日：2007-02-22
申请号：US11483432
申请日：2006-07-07
申请人： Didier Communi , Sabine Pirotton , Marc Parmentier , Jean-Marie Boeynaems
发明人： Didier Communi , Sabine Pirotton , Marc Parmentier , Jean-Marie Boeynaems
IPC分类号： A01K67/027
CPC分类号： C07K14/705 , A01K2217/05 , A01K2217/075 , C12N2310/14
摘要： This invention provides a receptor having a preference for pyrimidine nucleotides preferably uridine triphosphate over purine nucleotides. A receptor having a preference for pyrimidine nucleotides over purine nucleotides means a receptor for which pyrimidine nucleotides and purine nucleotides are not equally active and equipotent. This means that the receptor according to the invention in presence of these agonists presents a functional response (preferably the accumulation of Inositol triphosphate (IP3), diacylglycerol (DAG), or calcium ions) to lower concentration of pyrimidine nucleotides, preferably uridine triphosphate, than to purine nucleotides or a more important functional response to similar concentration of pyrimidine nucleotide than to purine nucleotide
摘要翻译：本发明提供了对嘌呤核苷酸优先选择嘧啶核苷酸优选尿苷三磷酸的受体。对嘌呤核苷酸优先选择嘧啶核苷酸的受体是指嘧啶核苷酸和嘌呤核苷酸不具有同等活性和等同性的受体。这意味着在这些激动剂存在下，根据本发明的受体具有功能性反应（优选三聚磷酸肌醇（IP3），二酰基甘油（DAG）或钙离子）的积累）以降低嘧啶核苷酸浓度，优选尿苷三磷酸嘌呤核苷酸或与嘌呤核苷酸相似浓度的嘧啶核苷酸的更重要的功能反应

3. 发明授权

US07312317B2 P2Y4 antibodies 有权
标题翻译： P2Y4抗体
公开(公告)号：US07312317B2
公开(公告)日：2007-12-25
申请号：US10811198
申请日：2004-03-26
申请人： Didier Communi , Jean-Marie Boeynaems , Marc Parmentier , Sabine Pirotton
发明人： Didier Communi , Jean-Marie Boeynaems , Marc Parmentier , Sabine Pirotton
IPC分类号： C07K16/18 , A61K39/395
CPC分类号： C07K14/705 , A01K2217/05 , A01K2217/075 , C12N2310/14
摘要： This invention provides a receptor having a preference for pyrimidine nucleotides preferably uridine triphosphate over purine nucleotides. A receptor having a preference for pyrimidine nucleotides over purine nucleotides means a receptor for which pyrimidine nucleotides and purine nucleotides are not equally active and equipotent. This means that the receptor according to the invention in presence of these agonists presents a functional response (preferably the accumulation of Inositol triphosphate (IP3), diacylglycerol (DAG), or calcium ions) to lower concentration of pyrimidine nucleotides, preferably uridine triphosphate, than to purine nucleotides or a more important functional response to similar concentration of pyrimidine nucleotide than to purine nucleotide.
摘要翻译：本发明提供了对嘌呤核苷酸优先选择嘧啶核苷酸优选尿苷三磷酸的受体。对嘌呤核苷酸优先选择嘧啶核苷酸的受体是指嘧啶核苷酸和嘌呤核苷酸不具有同等活性和等同性的受体。这意味着在这些激动剂存在下，根据本发明的受体具有功能性反应（优选三聚磷酸肌醇（IP3），二酰基甘油（DAG）或钙离子）的积累）以降低嘧啶核苷酸浓度，优选尿苷三磷酸嘌呤核苷酸或与嘌呤核苷酸相似浓度的嘧啶核苷酸的更重要的功能反应。

4. 发明授权

US06790626B2 Human pyrimidine receptor 有权
标题翻译：人嘧啶受体
公开(公告)号：US06790626B2
公开(公告)日：2004-09-14
申请号：US09077173
申请日：1998-11-12
申请人： Didier Communi , Sabine Pirotton , Marc Parmentier , Jean-Marie Boeynaems
发明人： Didier Communi , Sabine Pirotton , Marc Parmentier , Jean-Marie Boeynaems
IPC分类号： G01N33566
CPC分类号： C07K14/705 , A01K2217/05 , A01K2217/075 , C12N2310/14
摘要： The present invention concerns a new receptor having a preference for pyrimidine nucleotides, preferably UTP, or purine nucleotides and UDP, and which has an amino acid sequence having more than 60% homology with the amino acid sequence shown in FIG. 1.
摘要翻译：本发明涉及一种优选嘧啶核苷酸，优选UTP或嘌呤核苷酸和UDP的新受体，其具有与图1所示的氨基酸序列具有超过60％同源性的氨基酸序列。 1。

5. 发明申请

US20100278880A1 PHARMACEUTICAL FORMULATION FOR ALLERGEN PREPARATION 审中-公开
标题翻译：用于过敏制剂的药物制剂
公开(公告)号：US20100278880A1
公开(公告)日：2010-11-04
申请号：US12810536
申请日：2008-12-30
申请人： Thierry Legon , Sabine Pirotton , Gael Placier , Gilles Kergoat
发明人： Thierry Legon , Sabine Pirotton , Gael Placier , Gilles Kergoat
IPC分类号： A61K9/00 , A61K39/35
CPC分类号： A61K39/35 , A61K39/36 , A61K2039/542 , A61K2039/6087
摘要： Method for the production of a purified extract of natural allergens comprising the steps of extracting a natural source of allergens comprising allergenic proteins, purifying of said extract to remove non-protein components denaturating said purified extract, said purified denaturated extract comprising proteins, wherein the most abundant (w/w) proteins, forming together at least 60% (w/w) of all proteins, are at least two proteins, and all proteins represent at least 60% (w/w) of the dry weight of the purified denaturated extract or a method for the production of a purified extract of natural allergens comprising the steps of hydrolysing a denaturated allergen purifying said allergen hydrolysate to remove peptides with a molecular weight above 10,000 Da and below 1,000 Da in order to obtain a purified hydrolysate where 70%, more preferably 80% of the peptides are between 10,000 Da and 1,000 Da, in the form of an starch based pellet.
摘要翻译：用于生产天然过敏原纯化提取物的方法，包括以下步骤：提取包含过敏原蛋白质的天然过敏原来源，纯化所述提取物以除去使所述纯化提取物变性的非蛋白质组分，所述纯化的变性提取物包含蛋白质，其中最多含有至少60％（w / w）的所有蛋白质的丰富的（w / w）蛋白质是至少两种蛋白质，所有蛋白质代表纯化变性干重的至少60％（w / w）提取物或生产天然过敏原纯化提取物的方法，包括以下步骤：将纯化所述变应原水解产物的变性过敏原水解除去分子量高于10,000Da且低于1,000Da的肽，以获得纯化的水解产物，其中70％更优选80％的肽在10,000Da和1,000Da之间，以淀粉基丸的形式。

6. 发明申请

US20140255449A1 DOSAGE OF DNAK 审中-公开
标题翻译： DNAK的剂量
公开(公告)号：US20140255449A1
公开(公告)日：2014-09-11
申请号：US14233584
申请日：2012-07-19
申请人： Thierry Legon , Sabine Pirotton , Jean Duchateau
发明人： Thierry Legon , Sabine Pirotton , Jean Duchateau
IPC分类号： A61K39/36 , A61K39/39
CPC分类号： A61K39/36 , A61K39/0008 , A61K39/35 , A61K39/39 , A61K2039/545 , A61K2039/55516 , A61K2039/6043
摘要： A pharmaceutical preparation for subcutaneous injection comprising between 0.5 ng and 200 μg of HSP70 between 0.5 and 100 μg of fragments of an antigenic structure.
摘要翻译：一种用于皮下注射的药物制剂，其包含0.5至200μg的抗原结构片段的0.5至100μg之间的HSP70。

7. 发明申请

US20090324650A1 Method for The Production of Hydrolyzed Allergen 审中-公开
标题翻译：水解过敏原生产方法
公开(公告)号：US20090324650A1
公开(公告)日：2009-12-31
申请号：US12308859
申请日：2007-06-28
申请人： Thierry Legon , Sabine Pirotton , Gael Placier , Gilles Kergoat
发明人： Thierry Legon , Sabine Pirotton , Gael Placier , Gilles Kergoat
IPC分类号： A61K39/35 , C07K1/00 , C07K1/14 , C07K1/16 , C07K1/18 , C07K1/22 , C07K1/30 , C07K14/00 , C07K1/20 , A61P37/08
CPC分类号： A61K39/35 , A61K39/36 , A61K2039/542 , C07K14/415 , C12P21/06
摘要： A method for the production of a purified extract of natural allergens comprising the steps of a) extracting a natural source of allergens comprising allergenic proteins to form an extract, b) purifying of said extract to remove non-protein components to form a purified extract c) denaturating said purified extract to form a purified denaturated extract, said purified denaturated extract comprising proteins, wherein the most abundant (w/w) proteins, forming together at least 60% (w/w) of all proteins, are at least two proteins, and all proteins represent at least 60% (w/w) of the dry weight of the purified denaturated extract and a method for the production of a purified extract of natural allergens comprising the steps of a) hydrolysing a denaturated allergen to form an allergen hydrolysate, b) purifying said allergen hydrolysate to remove peptides with a molecular weight above 10,000 Da and below 1,000 Da in order to obtain a purified hydrolysate where 70%, more preferably 80% of the peptides are between 10,000 Da and 1,000 Da.
摘要翻译：一种用于生产天然过敏原纯化提取物的方法，包括以下步骤：a）提取包含过敏原蛋白质的天然过敏原来源以形成提取物，b）纯化所述提取物以除去非蛋白质组分以形成纯化的提取物c ）使所述纯化的提取物变性以形成纯化的变性提取物，所述纯化的变性提取物包含蛋白质，其中形成所有蛋白质至少60％（w / w）的最丰富的（w / w）蛋白质是至少两种蛋白质，并且所有蛋白质代表纯化的变性提取物的干重的至少60％（w / w），以及用于生产纯化的天然过敏原提取物的方法，包括以下步骤：a）水解变性变应原以形成变应原水解物，b）纯化所述变应原水解产物以除去分子量高于10,000Da且低于1,000Da的肽，以获得纯化的水解产物，其中70％，更优选80％肽在10,000Da和1,000Da之间。

8. 发明授权

US08735122B2 Method for the purification of heat shock proteins 有权
标题翻译：热休克蛋白纯化方法
公开(公告)号：US08735122B2
公开(公告)日：2014-05-27
申请号：US12311755
申请日：2007-10-12
申请人： Frederic Henot , Thierry Legon , Sabine Pirotton , Gael Placier
发明人： Frederic Henot , Thierry Legon , Sabine Pirotton , Gael Placier
IPC分类号： C12N9/14 , A23J1/00 , A61K38/43
CPC分类号： C07K14/47
摘要： Recombinant purified DnaK—having a ATPase activity without the addition of an other chaperone protein—essentially free of T-cell stimulating impurities.
摘要翻译：重组纯化的DnaK-具有ATP酶活性而不添加其它伴侣蛋白 - 基本上不含T细胞刺激杂质。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式